Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

How Are Oncology Practices Communicating Value-Based Care to Employers and Patients?
August 14th 2019

How Are Oncology Practices Communicating Value-Based Care to Employers and Patients?

On this episode of Managed Care Cast, we’re bringing you a portion of a panel discussion about the Oncology Care Model, held in July 2019 during a meeting of The Institute for Value-Based Medicine® (IVBM), an initiative of The American Journal of Managed Care®. At IVBM events, we gather thought leaders to share best practices across medicine, pharmacy, and management in regional locations around the country. This podcast is taken from our meeting focusing on Innovation and Quality in Oncology Care.
Study Finds Familial Risks of Second Primary Cancers for Patients With Malignant Melanoma
August 11th 2019

Study Finds Familial Risks of Second Primary Cancers for Patients With Malignant Melanoma

Alison Rodriguez
As survival rates for malignant melanoma increase, so does the likelihood that some patients will develop second primary cancers.
Podcast: This Week in Managed Care—Pancreatic Cancer Screening and Other Health News
August 11th 2019

Podcast: This Week in Managed Care—Pancreatic Cancer Screening and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
OneOncology Has Begun Administering Bevacizumab, Trastuzumab Biosimilars
August 8th 2019

OneOncology Has Begun Administering Bevacizumab, Trastuzumab Biosimilars

Jaime Rosenberg
Weeks after the first 2 anticancer biosimilars entered the US market, OneOncology announced that its partner practices have already started administering the drugs.
Lani Alison on How Innovation Is Being Used to Improve Quality Metrics in Oncology
August 6th 2019

Lani Alison on How Innovation Is Being Used to Improve Quality Metrics in Oncology

Innovation is being used to improve quality metrics in oncology care at the patient forefront and in data, explained Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates.
One Dose of HPV Vaccine Effective in Preventing Cervical Cancer Compared With Multiple Doses, Researchers Say
August 5th 2019

One Dose of HPV Vaccine Effective in Preventing Cervical Cancer Compared With Multiple Doses, Researchers Say

Matthew Gavidia
A single-dose human papillomavirus (HPV) vaccination strategy could be effective in less developed countries, where cost is in consideration.
How Are States Dealing With Challenges Facing Patients With Cancer?
July 31st 2019

How Are States Dealing With Challenges Facing Patients With Cancer?

Jaime Rosenberg
High costs of care, particularly for prescription drugs, dominated a discussion of cancer care at the state level during the June 27, 2019, National Comprehensive Cancer Network Policy Summit in Washington, DC.
Hospitals Affiliated With Top-Ranked Cancer Hospitals Have Modest Safety Advantage for Cancer Surgery
July 28th 2019

Hospitals Affiliated With Top-Ranked Cancer Hospitals Have Modest Safety Advantage for Cancer Surgery

Alison Rodriguez
The study found that the advantage was due to factors that affect hospital safety, which were present before affiliation and increased afterward.
Nivolumab, Ipilimumab Combo Yields Clinically Meaningful Responses in Advanced Hepatocellular Carcinoma
July 22nd 2019

Nivolumab, Ipilimumab Combo Yields Clinically Meaningful Responses in Advanced Hepatocellular Carcinoma

Jaime Rosenberg
Nivolumab (Opdivo) monotherapy is currently indicated for the treatment of patients with hepatocellular carcinoma who were previously treated with the targeted therapy sorafenib, sold as Nexavar, based on the CheckMate 040 trial. Assessing the safety and efficacy of nivolumab in combination with ipilimumab (Yervoy) among these patients, researchers have observed clinically meaningful responses and an acceptable safety profile.
New Monoclonal Antibody Targeting MFAP5 Shows Activity Against Ovarian, Pancreatic Tumors, Study Says
July 22nd 2019

New Monoclonal Antibody Targeting MFAP5 Shows Activity Against Ovarian, Pancreatic Tumors, Study Says

Alison Rodriguez
Researchers from Houston Methodist Cancer Center and The University of Texas MD Anderson Cancer Center said they demonstrated a new monoclonal antibody blocked ovarian and pancreatic tumor activity in mice.
Report: Majority of Hospitals Do Not Perform High-Risk Procedures Enough to Meet Safety Standards
July 19th 2019

Report: Majority of Hospitals Do Not Perform High-Risk Procedures Enough to Meet Safety Standards

Laura Joszt, MA
When it comes to performing high-risk procedures, the majority of hospitals do not perform them often enough to meet safety standards, according to a new report from The Leapfrog Group.
Personalized Cancer Vaccine Yields Promising Results for Patients With High-Risk Melanoma
July 18th 2019

Personalized Cancer Vaccine Yields Promising Results for Patients With High-Risk Melanoma

Jaime Rosenberg
A phase 2b clinical trial is producing promising results for a personalized cancer vaccine used in patients with stage III and IV resected melanoma.
Site Logo
July 16th 2019

AJMCtv Interviews: ASCO 2019

Jaime Rosenberg Samantha DiGrande
Site Logo
July 16th 2019

Medical World News: Managed Care Updates

Laura Joszt, MA Jaime Rosenberg Allison Inserro Mary Caffrey Samantha DiGrande
Financial toxicity, ACO contracts, removing barriers to care.
Site Logo
July 16th 2019

Research Report: ASCO 2019

Jaime Rosenberg Wallace Stephens
Selected abstracts from the 2019 Annual Meeting of the American Society of Clinical Oncology.
Site Logo
July 16th 2019

Biosimilars: ASCO 2019

Kelly Davio
Research on biosimilars presented at the 2019 Annual Meeting of the American Society of Clinical Oncology.
Site Logo
July 16th 2019

Policy Updates: ASCO 2019

Samantha DiGrande
From the Oncology Care Model to the possibilities of cannabis, policy issues drew big crowds at the 2019 Annual Meeting of the American Society of Clinical Oncology.
Site Logo
July 16th 2019

Cost of Care: Outlining the Risks That Go Along With the Benefit of CAR T-Cell Therapy

Samantha DiGrande
Cytokine release syndrome represents a major concern, and source of costs, associated with the life-saving gene therapy.
Site Logo
July 16th 2019

How Real-World Data Can Affect NSCLC Treatment

Samantha DiGrande
Real-world evidence is being embraced by FDA as a way to expand the review of data beyond the trial population, which may not be representative of the patients seen in clinics on a daily basis.
Site Logo
July 16th 2019

Clinical Findings

Jaime Rosenberg Mary K. Caffrey Allison Inserro
Clinical findings presented at the 2019 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.
Nivolumab, Ipilimumab Combo Demonstrates Clinical Benefit Among Adults With Pediatric Solid Tumors
July 15th 2019

Nivolumab, Ipilimumab Combo Demonstrates Clinical Benefit Among Adults With Pediatric Solid Tumors

Jaime Rosenberg
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) demonstrated significant clinical benefit in patients with solid pediatric tumors that progressed in adulthood, a patient population with few treatment options, according to study findings presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.
UK Cancer Group Warns That Obesity Is Overtaking Smoking as Disease Driver
July 14th 2019

UK Cancer Group Warns That Obesity Is Overtaking Smoking as Disease Driver

Alison Rodriguez
Although smoking cigarettes is thought of as being the most prevalent—yet preventable—cancer risk, new data suggests people who are obese now outnumber people who smoke, with excess weight causing more cases of certain cancers than smoking in the United Kingdom.
CMS Proposes Bundled Payments for Radiation Oncology
July 11th 2019

CMS Proposes Bundled Payments for Radiation Oncology

Jaime Rosenberg
CMS has proposed the mandatory Radiation Oncology Model, which would cover radiation therapy spanning a 90-day episode.
Authors Outline Steps to Better Imaging in Oncology
July 9th 2019

Authors Outline Steps to Better Imaging in Oncology

Mary Caffrey
Poor interpretation of imaging is the top reason for oncology malpractice lawsuits.
What Affects Time to Diagnosis in Children, Adolescents, and Young Adults With Solid Tumors?
July 8th 2019

What Affects Time to Diagnosis in Children, Adolescents, and Young Adults With Solid Tumors?

Wallace Stephens
Time to diagnosis, the interval that passes from first symptom presentation until diagnosis, varies by cancer type among children, adolescents, and young adults and may be affected by clinical and sociodemogrpahic factors.
Dr Bruce Feinberg on Why People Want to See the End of Chemotherapy in Cancer Treatment
July 6th 2019

Dr Bruce Feinberg on Why People Want to See the End of Chemotherapy in Cancer Treatment

New innovations in cancer therapies have people excited to leave behind the treatments of old, but it might not be time yet to throw away chemotherapy, said Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions.
Shifting Regulatory Action to States: Implications for Patient Access to High-Quality Cancer Care
July 3rd 2019

Shifting Regulatory Action to States: Implications for Patient Access to High-Quality Cancer Care

Jaime Rosenberg
Last week, a panel of diverse stakeholders took the stage at the National Comprehensive Cancer Network Policy Summit in Washington, DC, to discuss shifting regulatory action from the federal to the state level, and the possible implications for patient access to high-quality cancer care.
Can Nivolumab Effectively Treat Metastatic RCC When Resources Are Limited?
July 1st 2019

Can Nivolumab Effectively Treat Metastatic RCC When Resources Are Limited?

Wallace Stephens
Evidence has shown that nivolumab immunotherapy could effectively treat metastatic renal cell carcinoma (RCC) in settings where resources are constrained.
AJMC® Research Roundup: June 2019
June 28th 2019

AJMC® Research Roundup: June 2019

Here are 5 interesting findings from the June 2019 issue of AJMC®.
Dr Bruce Feinberg: Are We Past the Point of Researching Chemotherapy in Cancer?
June 28th 2019

Dr Bruce Feinberg: Are We Past the Point of Researching Chemotherapy in Cancer?

If chemotherapy is still going to be used for another decade, there needs to be continued research into it and how to improve quality of life for patients treated with it, said Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions.
<1
...
242526272829303132
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo